ATE448785T1 - Behandlung von entzündlicher darmerkrankung - Google Patents

Behandlung von entzündlicher darmerkrankung

Info

Publication number
ATE448785T1
ATE448785T1 AT05846549T AT05846549T ATE448785T1 AT E448785 T1 ATE448785 T1 AT E448785T1 AT 05846549 T AT05846549 T AT 05846549T AT 05846549 T AT05846549 T AT 05846549T AT E448785 T1 ATE448785 T1 AT E448785T1
Authority
AT
Austria
Prior art keywords
inflammatory bowel
bowel disease
treatment
animal
analog
Prior art date
Application number
AT05846549T
Other languages
English (en)
Inventor
David Old
Danny Dinh
Karen Kedzie
Daniel Gil
Wha Im
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE448785T1 publication Critical patent/ATE448785T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • C07D211/76Oxygen atoms attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05846549T 2004-11-29 2005-11-22 Behandlung von entzündlicher darmerkrankung ATE448785T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/999,451 US7326716B2 (en) 2003-06-06 2004-11-29 Treatment of inflammatory bowel disease
PCT/US2005/042467 WO2006058080A1 (en) 2004-11-29 2005-11-22 Treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
ATE448785T1 true ATE448785T1 (de) 2009-12-15

Family

ID=35903405

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05846549T ATE448785T1 (de) 2004-11-29 2005-11-22 Behandlung von entzündlicher darmerkrankung

Country Status (10)

Country Link
US (1) US7326716B2 (de)
EP (1) EP1817033B1 (de)
AT (1) ATE448785T1 (de)
AU (1) AU2005309622A1 (de)
BR (1) BRPI0518690A2 (de)
CA (1) CA2589438C (de)
DE (1) DE602005017815D1 (de)
DK (1) DK1817033T3 (de)
ES (1) ES2334374T3 (de)
WO (1) WO2006058080A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700627B2 (en) * 2006-07-26 2010-04-20 Allergan, Inc. Therapeutic substituted lactams
CN102065864B (zh) * 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
EP2198879A1 (de) 2008-12-11 2010-06-23 Institut Curie CD74-modulierender Wirkstoff zur Regulierung der Dendritenzellmigration und Verfahren zur Untersuchung der Bewegungsfähigkeit einer Zelle
EP2199273B1 (de) 2008-12-18 2018-02-21 Agfa Nv Polymerisierbare Fotoinitiatoren und strahlungshärtbare Zusammensetzungen
US8883873B2 (en) 2009-05-18 2014-11-11 Agfa Graphics Nv Polymerizable polymeric photoinitiators and radiation curable compositions
WO2011047048A1 (en) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
EP2447259B1 (de) 2010-10-20 2016-03-16 Agfa Graphics N.V. Polymerisierbare Fotoinitiatoren für LED-härtbare Zusammensetzungen
AU2013344878A1 (en) * 2012-11-16 2015-05-21 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin EP4 agonist combinations
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス,インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
EP2868650B1 (de) 2013-10-30 2018-08-08 Agfa Nv Synthese von Acetalverbindungen unter Verwendung von zwitterionischen Katalysatoren
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
SE520947C2 (sv) * 2002-01-18 2003-09-16 Aneo Ab Ventilarrangemang för blandning av två medier
WO2004029581A2 (en) * 2002-09-26 2004-04-08 The Children's Hospital Of Philadelphia Method of determining surface binding capacity
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CN1735597A (zh) * 2003-01-10 2006-02-15 霍夫曼-拉罗奇有限公司 作为前列腺素激动剂的2-哌啶酮衍生物
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US6747037B1 (en) * 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
US6977260B2 (en) * 2004-01-22 2005-12-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
DE10341727A1 (de) * 2003-09-10 2005-04-28 Starck H C Gmbh Reinigung von Ammoniummetallat-Lösungen
DK1761495T3 (da) 2004-06-04 2012-06-18 Allergan Inc Piperidinylprostaglandinanaloge som midler til nedsættelse af øjets indre tryk

Also Published As

Publication number Publication date
AU2005309622A1 (en) 2006-06-01
EP1817033B1 (de) 2009-11-18
DK1817033T3 (da) 2010-03-08
DE602005017815D1 (de) 2009-12-31
WO2006058080A1 (en) 2006-06-01
CA2589438C (en) 2014-07-22
EP1817033A1 (de) 2007-08-15
ES2334374T3 (es) 2010-03-09
US7326716B2 (en) 2008-02-05
US20050171062A1 (en) 2005-08-04
BRPI0518690A2 (pt) 2008-12-02
CA2589438A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
ATE448785T1 (de) Behandlung von entzündlicher darmerkrankung
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA200601239A1 (ru) Замещённые хинолиновые соединения
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
CY1111437T1 (el) Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
ECSP066684A (es) Nitrooxiderivados de prostaglandinas
MA31086B1 (fr) Formulations de doses unitaires et procedes de traitement d'une thrombose avec un inhibiteur oral du facteur xa.
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
UY28280A1 (es) 2- hidroxi - 3- diaminoalcanos de benzamida
ATE432260T1 (de) Pyridinderivate als pkc-theta-hemmer
ATE424208T1 (de) Proteinkinaseinhibitoren
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
ATE491453T1 (de) Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
EA200970436A1 (ru) Соединения карбамата для лечения депрессии
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties